Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is required. 5 mg only: Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males. REDEX is not indicated for use by women.

Posology

Erectile dysfunction in adult Men In general,

the recommended dose is 10 mg taken prior to anticipated sexual activity and with or without food.

In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be tried. It may be taken at least 30 minutes prior to sexual activity.

The maximum dose frequency is once per day. Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not recommended for continuous daily use. In patients who anticipate a frequent use of REDEX (i.e., at least twice weekly) a once daily regimen with the lowest doses of REDEX might be considered suitable, based on patient choice and the physician's judgement. In these patients, the recommended dose is 5mg taken once a day at approximately the same time of day.

The dose may be decreased to 2.5mg once a day based on individual tolerability. The appropriateness of continued use of the daily regimen should be reassessed periodically. Benign prostatic hyperplasia in adult men (tadalafil 5 mg only) The recommended dose is 5 mg, taken at approximately the same time every day with or without food. For adult men being treated for both benign prostatic hyperplasia and erectile dysfunction the recommended dose is also 5 mg taken at approximately the same time every day. Patients who are unable to tolerate tadalafil 5 mg for the treatment of benign prostatic hyperplasia should consider an alternative therapy as the efficacy of tadalafil 2.5 mg for the treatment of benign prostatic hyperplasia has not been demonstrated.

Special Populations

Elderly Men

Dose adjustments are not required in elderly patients.

Men with Renal Impairment

Dose adjustments are not required in patients with mild to moderate renal impairment. For patients with severe renal impairment, 10 mg is the maximum recommended dose. Once-a-day dosing of 2.5 or 5 mg tadalafil both for the treatment of erectile dysfunction or benign prostatic hyperplasia is not recommended in patients with severe renal impairment (see sections 4.4 and 5.2).

Men with Hepatic Impairment

For the treatment of erectile dysfunction using on-demand REDEX the recommended dose of REDEX is 10 mg taken prior to anticipated sexual activity and with or without food. There is limited clinical data on the safety of REDEX in patients with severe hepatic impairment (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician. There are no available data about the administration of doses higher than 10mg of tadalafil to patients with hepatic impairment. Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician (see sections 4.4 and 5.2).

Men with Diabetes

Dose adjustments are not required in diabetic patients. Paediatric population There is no relevant use of REDEX in the paediatric population with regard to the treatment of erectile dysfunction.

Method of administration

REDEX is available as 2.5, 5, 10, and 20 mg film-coated tablets for oral use.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of REDEX to patients who are using any form of organic nitrate is contraindicated (see section 4.5). REDEX must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated: - patients with myocardial infarction within the last 90 days, - patients with unstable angina or angina occurring during sexual intercourse, - patients with New York Heart Association Class 2 or greater heart failure in the last 6 months, - patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension, - patients with a stroke within the last 6 months. REDEX is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4). The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).

Before treatment with REDEX

A medical history and physical examination should be undertaken to diagnose erectile dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before pharmacological treatment is considered. Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1) and as such potentiates the hypotensive effect of nitrates (see section 4.3).

The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following an appropriate medical assessment.

It is not known if REDEX is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy. Tadalafil 5 mg - Prior to initiating treatment with tadalafil for benign prostatic hyperplasia patients should be examined to rule out the presence of carcinoma of the prostate and carefully assessed for cardiovascular conditions (see section 4.3).

Cardiovascular

Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain, palpitations and tachycardia, have been reported either post marketing and/or in clinical trials. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to REDEX, to sexual activity, or to a combination of these or other factors.

Tadalafil 2.5 mg and 5 mg - In patients receiving concomitant antihypertensive medicinal products, tadalafil may induce a blood pressure decrease. When initiating daily treatment with tadalafil, appropriate clinical considerations should be given to a possible dose adjustment of the antihypertensive therapy. In patients who are taking alpha1 blockers, concomitant administration of REDEX may lead to symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and doxazosin is not recommended.

Vision

Visual defects and cases of NAION have been reported in connection with the intake of REDEX and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he should stop taking REDEX and consult a physician immediately (see section 4.3).

Renal and hepatic impairment

(tadalafil 2.5 mg and 5 mg) Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to influence clearance by dialysis, once-a-day dosing of REDEX is not recommended in patients with severe renal impairment. There is limited clinical data on the safety of single-dose administration of REDEX in patients with severe hepatic insufficiency (Child-Pugh Class C).

Once-a-day administration has not been evaluated in patients with hepatic insufficiency.

If REDEX is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.

Hepatic impairment (tadalafil 10 mg and 20 mg)

There is limited clinical data on the safety of single-dose administration of REDEX in patients with severe hepatic insufficiency (Child-Pugh Class C).

If REDEX is prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing physician.

Priapism and anatomical deformation of the penis

Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. REDEX, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).

Use with CYP3A4 inhibitors

Caution should be exercised when prescribing REDEX to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section 4.5).

REDEX and other treatments for erectile dysfunction

The safety and efficacy of combinations of REDEX and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. The patients should be informed not to take REDEX in such combinations.

Lactose

REDEX contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically  relevant interactions at higher doses cannot be completely ruled out.
Effects of Other Substances on Tadalafil
Cytochrome P450 inhibitors
Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole (200 
mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by 15%, relative to the AUC 
and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg) 
exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease inhibitor (200 mg twice daily), which 
is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg) exposure (AUC) 
2-fold with no change in Cmax. Although specific interactions have not been studied, other protease 
inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, 
itraconazole, and grapefruit juice, should be co-administered with caution, as they would be 
expected to increase plasma concentrations of tadalafil (see section 4.4). Consequently, the 
incidence of the adverse reactions listed in section 4.8 might be increased.
Transporters
The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not 
known. Therefore, there is the potential of drug interactions mediated by inhibition of 
transporters. Cytochrome P450 inducers
A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for 
tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of 
tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as 
phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of tadalafil.
Effects of Tadalafil on Other Medicinal Products
Nitrates
In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of 
nitrates. Therefore, administration of REDEX to patients who are using any form of organic nitrate 
is contraindicated (see section 4.3). Based on the results of a clinical study in which 150 
subjects receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at 
various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 
hours had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of REDEX 
(2.5 mg- 20 mg), where nitrate administration is deemed medically necessary in a life-threatening 
situation, at least 48 hours should have elapsed after the last dose of REDEX before nitrate 
administration is considered. In such circumstances, nitrates should only be administered under 
close medical supervision with appropriate haemodynamic monitoring.
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a 
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant 
manner. This effect lasts at least twelve hours and may be symptomatic, including syncope. 
Therefore, this combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not 
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in 
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be
initiated at minimal dosage and progressively adjusted.

In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal 
products were studied, including calcium-channel blockers (amlodipine), angiotensin converting 
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide 
diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or 
in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers). 
Tadalafil (10 mg, except for studies with angiotensin II receptor blockers and amlodipine in which 
a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In 
another clinical pharmacology study, tadalafil (20 mg) was studied in combination with up to 4 
classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood- 
pressure changes appeared to relate to the degree of blood pressure control. In this regard, study 
subjects whose blood pressure was well controlled, the reduction was minimal and similar to that 
seen in healthy subjects. In study subjects whose blood pressure was not controlled, the  reduction 
was greater, although this reduction was not associated with hypotensive symptoms in the majority 
of subjects. In patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg 
may induce a blood pressure decrease, which (with the exception of alpha- blockers - see above) is, 
in general, minor and not likely to be clinically relevant. Analysis of  Phase 3 clinical trial 
data showed no difference in adverse events in patients taking tadalafil with or without 
antihypertensive medicinal products. However, appropriate clinical advice should be given to 
patients regarding a possible decrease in blood pressure when they are treated with 
antihypertensive medicinal products.
Riociguat
Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5 inhibitors 
were combined with riociguat. In clinical studies, riociguat has been shown to augment the 
hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the 
combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including 
tadalafil, is contraindicated (see section 4.3).
5- alpha reductase inhibitors
In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo  
plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified. 
However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha 
reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil is 
co-administered with 5-ARIs.
CYP1A2 substrates (e.g. theophylline)
When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase 
inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only 
pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is minor 
and was of no clinical significance in this study, it should be considered when co- administering 
these medicinal products.
Ethinylestradiol and terbutaline
Tadalafil has been demonstrated to produce an increase in the oral bioavailability of 
ethinylestradiol; a similar increase may be expected with oral administration of terbutaline, 
although the clinical consequence of this is uncertain.
Alcohol
Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by co- 
administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations 
were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to 
maximise the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol). 
Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7 g/kg or 
approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects, postural 
dizziness and orthostatic hypotension were observed. When tadalafil was administered with lower 
doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with
similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented
by tadalafil (10 mg).
Cytochrome P450 metabolised medicinal products
Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance 
of medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does 
not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and 
CYP2C19.
CYP2C9 substrates (e.g. R-warfarin)
Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin  
or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by 
warfarin.
Aspirin
Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by 
acetylsalicylic acid.
Antidiabetic medicinal products
Specific interaction studies with antidiabetic medicinal products were not conducte
 

REDEX is not indicated for use by women.

Pregnancy

There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). As a precautionary measure, it is preferable to avoid the use of REDEX during pregnancy.

Breastfeeding

Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk. A risk to the suckling child cannot be excluded. REDEX should not be used during breast feeding.

Fertility

Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration was seen in some men (see sections 5.1 and 5.3).

REDEX has negligible influence on the ability to drive or use machines. Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to REDEX before driving or using machines.

Summary of the safety profile The most commonly reported adverse reactions in patients taking REDEX for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of REDEX. The adverse reactions reported were transient, and generally mild or moderate. The majority of headaches reported with REDEX once-a-day dosing are experienced within the first 10 to 30 days of starting treatment. Tabulated summary of adverse reactions The table below lists the adverse reactions observed from spontaneous reporting and in placebo-controlled clinical trials (comprising a total of 8022 patients on REDEX and 4422 patients on placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day treatment of benign prostatic hyperplasia. Frequency convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very Rare (<1/10,000) and Not known (cannot be estimated from the available data).

Very common	Common	Uncommon	Rare
Immune system disorders
		Hypersensitivity reactions	Angioedema2
Nervous system disorders
	Headache	Dizziness	Stroke1 (including haemorrhagic events), Syncope, Transient ischaemic attacks1, Migraine2, Seizures2, Transient amnesia
Eye disorders
		Blurred vision, Sensations described as eye pain	Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)2, Retinal vascular occlusion2
Ear and labyrinth disorders
		Tinnitus	Sudden hearing loss
Cardiac disorders1
		Tachycardia, Palpitations	Myocardial infarction, Unstable angina pectoris2, Ventricular arrhythmia2
Vascular disorders
	Flushing	Hypotension3, Hypertension
Respiratory, thoracic and mediastinal disorders
	Nasal congestion	Dyspnoea, Epistaxis
Gastrointestinal disorders
	Dyspepsia	Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux
Skin and subcutaneous tissue disorders
		Rash	Urticaria, Stevens-Johnson syndrome2, Exfoliative dermatitis2, Hyperhydrosis (sweating)
Musculoskeletal, connective tissue and bone disorders
	Back pain, Myalgia, Pain in extremity
Renal and urinary disorders
		Haematuria
Reproductive system and breast disorders
		Prolonged erections	Priapism, Penile haemorrhage, Haematospermia
General disorders and administration site conditions
		Chest pain1, Peripheral oedema, Fatigue	Facial oedema2, Sudden cardiac death1,2

(1) Most of the patients had pre-existing cardiovascular risk factors (see section 4.4).

(2) Postmarketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials.

(3) More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products. Description of selected adverse reactions A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported in patients treated with tadalafil once a day as compared with placebo. Most of these ECG abnormalities were not associated with adverse reactions. Other special populations Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials with tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported more frequently in patients over 65 years of age. In clinical trials with tadalafil 5 mg taken once a day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years of age. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie, United Kingdom: Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.

Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to 100 mg have been given to patients. Adverse events were similar to those seen at lower doses. In cases of overdose, standard supportive measures should be adopted, as required. Haemodialysis contributes negligibly to tadalafil elimination.

Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC code:
G04BE08.
Mechanism of action
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, 
inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This 
results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing 
an erection. Tadalafil has no effect in the treatment of erectile dysfunction in
the absence of sexual stimulation.
Tadalafil 5 mg - The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum  is 
also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The 
resulting vascular relaxation increases blood perfusion which may be the mechanism by which 
symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be complemented by 
inhibition of bladder afferent nerve activity and smooth muscle relaxation of the prostate and 
bladder.
Pharmacodynamic effects
Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme
found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal
muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5
than on other phosphodiesterases. Tadalafil is >10,000-fold more potent for PDE5 than for PDE1, 
PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other organs. 
Tadalafil is >10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and 
blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an enzyme involved 
in cardiac contractility. Additionally, tadalafil is approximately 700-fold more potent for PDE5 
than for PDE6, an enzyme which is found in the retina and is responsible for phototransduction. 
Tadalafil is also >10,000-fold more potent for PDE5 than for PDE7 through PDE10.
Clinical efficacy and safety
Tadalafil administered to healthy subjects produced no significant difference compared to placebo 
in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg, 
respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of 
0.2/4.6mmHg, respectively), and no significant change in heart rate.
In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination 
(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent 
with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports 
of changes in colour vision were rare (<0.1%).
Three studies were conducted in men to assess the potential effect on spermatogenesis of REDEX 10mg 
(one 6-month study) and 20mg (one 6-month and one 9-month study)
administered daily. In two of these studies decreases were observed in sperm count and 
concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not 
associated with changes in other parameters, such as motility, morphology, and FSH.
Erectile dysfunction
Three clinical studies were conducted in 1054 patients in an at-home setting to define the period 
of responsiveness to REDEX on demand. Tadalafil demonstrated statistically significant improvement 
in erectile function and the ability to have successful sexual intercourse up to 36 hours following 
dosing, as well as patients' ability to attain and maintain erections for successful intercourse 
compared to placebo as early as 16 minutes following dosing.
In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction 
secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to 
a mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg 
(flexible-dose, on demand) of 48% as compared to 17% with placebo.
Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients, 
including patients with erectile dysfunction of various severities (mild, moderate, severe), 
etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction  
of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of 
patients reported that REDEX improved their erections as compared to 35% with placebo. Also, 
patients with erectile dysfunction in all severity categories reported improved erections whilst 
taking REDEX (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared to 45%, 
42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts were 
successful in REDEX-treated patients as compared to 32% with placebo.
For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were 
initially conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, 
with erectile dysfunction of various severities (mild, moderate, severe) and etiologies. In the two 
primary efficacy studies of general populations, the mean per-subject proportion of successful 
intercourse attempts were 57 and 67% on REDEX 5mg, 50% on REDEX 2.5mg as compared to 31 and 37% 
with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the mean
per-subject proportion of successful attempts were 41 and 46% on REDEX 5mg and 2.5mg,
respectively, as compared to 28% with placebo. Most patients in these three studies were responders 
to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217 patients who were 
treatment-naive to PDE5 inhibitors were randomised to REDEX 5mg once a
day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was
68% for REDEX patients compared to 52% for patients on placebo.
Benign prostatic hyperplasia
REDEX was studied in 4 clinical studies of 12 weeks duration enrolling over 1500 patients with 
signs and symptoms of benign prostatic hyperplasia. The improvement in the total international 
prostate symptom score with REDEX 5mg in the four studies were -4.8, -5.6, -6.1 and -6.3 compared 
to -2.2, -3.6, -3.8 and -4.2 with placebo. The improvements in total international prostate symptom 
score occurred as early as 1 week. In one of the studies, which also included tamsulosin 0.4 mg as 
an active comparator, the improvement in total international prostate symptom score with REDEX 5mg, 
tamsulosin and placebo were -6.3, -5.7 and -4.2 respectively. One of these studies assessed 
improvements in erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in 
patients with both conditions. The improvements in the erectile function domain of the 
international index of erectile function and the total international prostate symptom score in this 
study were 6.5 and -6.1 with REDEX 5 mg compared to 1.8 and -3.8 with placebo, respectively. The 
mean per-subject proportion of successful sexual intercourse attempts was 71.9% with REDEX 5 mg 
compared to 48.3% with placebo.
The maintenance of the effect was evaluated in an open-label extension to one of the studies, which 
showed that the improvement in total international prostate symptom score seen at 12 weeks was 
maintained for up to 1 additional year of treatment with REDEX 5mg.
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies in all 
subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2
for information on paediatric use.
 

Absorption
Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute bioavailability  of tadalafil following oral dosing has not been determined.
The rate and extent of absorption of tadalafil are not influenced by food, thus REDEX may be taken 
with or without food. The time of dosing (morning versus evening) had no clinically relevant 
effects on the rate and extent of absorption.
Distribution
The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed 
into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. 
Protein binding is not affected by impaired renal function.
Less than 0.0005% of the administered dose appeared in the semen of healthy subjects. 
Biotransformation
Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major 
circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold 
less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at 
observed metabolite concentrations.
Elimination
The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy 
subjects.
Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately 
61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose). 
Linearity/Non-Linearity
Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a 
dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state
plasma concentrations are attained within 5 days of once daily dosing.
Pharmacokinetics determined with a population approach in patients with erectile dysfunction are
similar to pharmacokinetics in subjects without erectile dysfunction.

Special Populations
Elderly
Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in  
25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is 
not clinically significant and does not warrant a dose adjustment.
Renal Insufficiency
In clinical pharmacology studies using single dose tadalafil (5 to 20mg), tadalafil exposure (AUC) 
approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate 
(creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal 
disease on dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in healthy 
subjects. Haemodialysis contributes negligibly to tadalafil elimination.
Hepatic Insufficiency
Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh class A 
and B) is comparable to exposure in healthy subjects when a dose of 10 mg is administered. There is 
limited clinical data on the safety of REDEX in patients with severe hepatic insufficiency 
(Child-Pugh class C). If REDEX is prescribed, a careful individual benefit/risk evaluation should 
be undertaken by the prescribing physician. There are no available data about the administration of 
once-a-day dosing of tadalafil to patients with hepatic impairment. If REDEX is prescribed 
once-a-day, a careful individual benefit/risk evaluation should be undertaken by the prescribing 
physician. There are no available data about the administration of doses higher than 10 mg of 
tadalafil to patients with hepatic impairment.
Patients with Diabetes
Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC
value for healthy subjects. This difference in exposure does not warrant a dose adjustment.
 

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction. There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated free drug at this dose was approximately 18-times the human AUC at a 20 mg dose. There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. See also section 5.1.

Lactose Monohydrate
Croscarmellose Sodium
Microcrystalline Cellulose
Sodium Lauryl sulfate
Povidone K30
Magnesium Stearate
Yellow Iron Oxide Opadry II white.

Not applicable.

3 years

Do not store above 30°C.

Redex 5 is supplied in 3 blisters packs of 30 film coated tablets. Redex 10, 20 is supplied in blister packs of 2 or 5 film coated tablets. Not all pack sizes may be marketed

No special requirements.